Sun Pharma said it will take "appropriate action" in the wake of AP High Court suspending the co's $4 bn deal with Ranbaxy.

Shares of Ranbaxy, which is majority-owned by Japan’s Daiichi-Sankyo, saw an unusual increase in price and turnover during six trading days...

Shares of Sun Pharma and Ranbaxy slipped over 2% each in after the HC put the deal on hold until it decides on a petition alleging insider ...

Sun Pharma denied insider trading charges against Silverstreet Developers- its wholly owned arm - in the $4 bn acquisition deal of Ranbaxy ...